was successfully added to your cart.

Using PGx Testing to Optimize Clomipramine Dosing in Major Depression

Genetic Testing for Depression

 

An October 2016 article in the Journal of Clinical Pharmacy and Therapeutics , “The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report,” discusses the application of pharmacogenetic and pharmacokinetic analyses to assess the dosing of clomipramine to achieve therapeutic benefit in a clomipramine non-responder. In the study, a female patient with refractory major depression underwent pharmacogenetic testing to analyze her need for higher than normal doses of clomipramine. Specifically, PGx testing revealed polymorphisms in cytochrome P450 2D6 and 2C19 leads to interindividual differences in drug plasma concentrations, affecting clomipramine efficacy. The article concluded “[t]herapeutic drug monitoring and pharmacogenetic analyses may be useful in the investigation and optimization of clomipramine in standard-dose non-responders.”

Vardenafil

ABOUT RXIGHT®

Escitalopram

FIND A PHARMACY

Esomeprazole

CONTACT US TODAY

Related Post

Leave a Reply